Back to top
more

Veru (VERU)

(Delayed Data from NSDQ)

$0.37 USD

0.37
4,101,200

-0.08 (-18.72%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $0.37 0.00 (1.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Veru (VERU) Looks Ripe for Bottom Fishing

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Veru (VERU), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Veru (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Veru Inc. (VERU) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Veru (VERU) delivered earnings and revenue surprises of 14.29% and 86.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Cooper Companies (COO) Q4 Earnings Beat Estimates

by Zacks Equity Research

The Cooper Companies (COO) delivered earnings and revenue surprises of 4% and 0.89%, respectively, for the quarter ended October 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medtronic (MDT) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Medtronic (MDT) delivered earnings and revenue surprises of 1.61% and 1.75%, respectively, for the quarter ended October 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cue Biopharma (CUE) delivered earnings and revenue surprises of 15% and 205.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Veru (VERU) delivered earnings and revenue surprises of -16.67% and 12.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of -9.38% and 11.95%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Zacks Equity Research

Baxter (BAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.

Zacks Equity Research

What Makes Veru (VERU) a New Buy Stock

by Zacks Equity Research

Veru (VERU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Veru Inc. (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?

by Zacks Equity Research

Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.

Zacks Equity Research

Charles River (CRL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.

Zacks Equity Research

Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Verano Holdings Corp. (VRNOF) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 0% and 0.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of 35% and 59.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0% and 3.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vapotherm (VAPO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Vapotherm (VAPO) delivered earnings and revenue surprises of 23.68% and 4.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lantheus Holdings (LNTH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 15.79% and 4.97%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Blue Water (BWV) Up on Acquisition of 6 FDA-Approved Drugs

by Zacks Equity Research

Blue Water (BWV) soars 62% after declaring its deal to purchase six FDA-approved products for $8.5 million. The agreement will help expand the company's portfolio into cardiology and pain management.

Zacks Equity Research

Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of -33.33% and 66.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is a Surprise Coming for Veru (VERU) This Earnings Season?

by Zacks Equity Research

Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Veru Inc. (VERU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.